Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QuinAct: ACT Retreatment for Recurrent Malaria
NCT01374581Phase 3Completed
- Sponsor
- University of Antwerp
- Start
- May 2012
- Primary completion
- Jun 2014
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 3, randomised, open-label trial of artemether + lumefantrine and artesunate + amodiaquine in Malaria, sponsored by University of Antwerp. Started May 2012; status: completed.
02
Drugs
artemether + lumefantrineartesunate + amodiaquine
03
Conditions
Malaria
Beyond the preview
Go deeper on NCT01374581.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01374581.